top of page
Aromatase Inhibitors (AI) for Breast Cancer: Joint Pain, Bone Loss and How to Complete Your Treatment

Aromatase Inhibitors (AI) for Breast Cancer: Joint Pain, Bone Loss and How to Complete Your Treatment

ป้าหมอนุช
2 hours ago
5 min read

Aromatase inhibitors (AIs) — letrozole, anastrozole and exemestane — are key drugs for hormone receptor-positive (HR+) breast cancer in postmenopausal women, or in premenopausal women receiving ovarian suppression. They reduce the risk of recurrence and improve survival, and are usually taken for 5 years, sometimes 7–10 years. The most common side effects are joint pain, bone loss and hot flashes, most of which can be prevented or managed. At Namarak Hospital, bone density testing (DXA scan) is available on site, and our team monitors side effects and bone health throughout treatment so patients can complete their course — the key to successful treatment.

How do AIs work, and how do they differ from tamoxifen?

After menopause, the body still makes estrogen in fat and muscle through the aromatase enzyme. AIs block this enzyme and sharply lower estrogen levels, starving hormone-dependent cancer cells. Tamoxifen instead blocks the hormone receptor on cancer cells without lowering estrogen, so the side effects differ — see Tamoxifen side effects

  • AIs — joint pain, bone loss and a slight rise in cholesterol, but no increased risk of blood clots or uterine cancer

  • Tamoxifen — does not thin bones (it helps preserve bone after menopause) but slightly increases the risk of blood clots and uterine cancer

  • Your doctor chooses based on cancer risk, menopausal status and other health conditions — see HR+/HER2− breast cancer

Common side effects

  • Joint pain and stiffness (AI-associated arthralgia) — affects up to about half of users, typically hands, wrists, knees and ankles, worse on waking, usually starting in the first 2–3 months

  • Bone thinning and osteoporosis — faster bone loss and higher fracture risk

  • Hot flashes and night sweats

  • Vaginal dryness and painful intercourse

  • Fatigue, poor sleep, mood changes, mild hair thinning

  • A slight rise in cholesterol — check lipids and look after heart health

Protecting your bones on AIs

AIs cause ongoing bone loss throughout treatment, so international guidelines recommend assessment and prevention from the start.

  • Bone mineral density test (DXA scan) before starting and every 1–2 years depending on risk — available at Namarak Hospital

  • Enough calcium and vitamin D, mainly from food, with supplements if needed and vitamin D levels checked as appropriate

  • Weight-bearing and muscle-strengthening exercise, such as brisk walking and light weights — good for bones and joint pain

  • No smoking, limited alcohol and fall prevention

  • Bone-modifying agents — bisphosphonates (e.g. zoledronic acid) or denosumab — considered when bone density is low (e.g. T-score below −2.0) or there are several fracture risk factors

Extra benefit of bisphosphonates after menopause

Beyond protecting bone, the ASCO–Ontario Health guideline recommends considering adjuvant bisphosphonates, such as zoledronic acid every 6 months for 3 years, in postmenopausal women with early breast cancer who are candidates for adjuvant therapy, because they reduce bone recurrence and slightly improve survival. A dental check and any needed dental work should be done before starting, because of a very small risk of osteonecrosis of the jaw.

Caution: if you receive denosumab, do not stop it on your own — bone loss can rebound quickly and cause multiple spinal fractures. Plan any change with your doctor.

Managing joint pain

  • Regular exercise — the HOPE trial showed aerobic plus strength exercise reduced AI joint pain

  • Acupuncture — the SWOG S1200 trial found it reduced pain more than sham acupuncture

  • Duloxetine — the SWOG S1202 trial showed it reduced AI-associated joint pain

  • Short courses of paracetamol or NSAIDs as advised by your doctor

  • Switching to another AI or to tamoxifen if symptoms persist — many patients tolerate the new drug better

Do not stop your medicine on your own. If symptoms are severe, tell your doctor — incomplete treatment reduces protection against recurrence.

Hot flashes and vaginal dryness

  • Hot flashes — layered clothing, cooler rooms, less caffeine and alcohol, exercise; if troublesome, your doctor may consider non-hormonal drugs such as venlafaxine or gabapentin

  • Vaginal dryness — regular vaginal moisturizers and lubricants during intercourse

  • Systemic hormone replacement should not be used; low-dose vaginal estrogen must always be discussed with your cancer doctor first

How long do I take it?

Usually 5 years. Patients at higher risk of recurrence, such as those with positive lymph nodes, may benefit from a total of 7–10 years, balanced against side effects, especially bone health. Some high-risk patients may also receive a CDK4/6 inhibitor (abemaciclib or ribociclib) with endocrine therapy in the first years.

Frequently asked questions (FAQ)

Will AI joint pain go away?

It often improves with regular exercise, acupuncture or medication, and resolves after treatment ends. If it is intolerable, your doctor can switch to another AI or to tamoxifen.

How often should I check bone density on an AI?

Have a DXA scan before starting and every 1–2 years depending on risk, together with adequate calcium and vitamin D.

Can I stop the medicine because of side effects?

Do not stop on your own, as incomplete treatment reduces protection against recurrence. Tell your doctor so treatment can be adjusted; most side effects can be managed.

How do AIs differ from tamoxifen?

AIs lower estrogen levels and are used after menopause or with ovarian suppression. Tamoxifen blocks hormone receptors on cancer cells and can be used before or after menopause, so their side effects differ.

How many years do I need to take an AI?

Usually 5 years; higher-risk patients may continue to a total of 7–10 years depending on cancer risk and bone health.

About Namarak Hospital

Namarak Hospital is a specialized breast and breast cancer hospital in Bangkok, providing complete care in one place — from diagnosis with 3D mammography, ultrasound, automated breast ultrasound (ABUS) and biopsy to comprehensive breast cancer treatment, including breast-conserving and reconstructive surgery, intraoperative radiotherapy (IORT), chemotherapy, targeted therapy and endocrine therapy, planned by a multidisciplinary team according to the latest international guidelines. See Breast cancer treatment: a complete guide, contact us on LINE, tel. +66 2 059 0245, or our Second Opinion service.

Related articles

References

  • Eisen A, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO–OH (CCO) Guideline Update. J Clin Oncol 2022;40:787–800

  • Hadji P, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement. J Bone Oncol 2025

  • Hershman DL, et al. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors (SWOG S1200). JAMA 2018;320:167–76

  • Henry NL, et al. Randomized Placebo-Controlled Trial of Duloxetine for Aromatase Inhibitor-Associated Arthralgias (SWOG S1202). J Clin Oncol 2018;36:326–32

  • Irwin ML, et al. Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia (HOPE). J Clin Oncol 2015;33:1104–11

  • NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026

Medically reviewed by: Namarak Hospital medical team · Last checked: 17 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.

Comments


Link to the Namarak Hospital medical team profiles
bottom of page